Follicular Lymphoma · line 1 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | surveillance |
| Linked regimen | None |
| ID | IND-FL-1L-WATCH |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-FL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Surveillance track default for FL low-burden 1L. Engine routes to BR (standard) on RF-FL-HIGH-TUMOR-BURDEN-GELF, to R-CHOP (aggressive) on RF-FL-TRANSFORMATION-SUSPECT.
Used By
Algorithms
ALGO-FL-1L- ALGO-FL-1L